drugset / Trial / NCT06231550
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2025-03-18
- Completion
- 2025-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FC084CSA | Unknown | 100 mg | — |
| Subject | FC084CSA | Unknown | 200 mg | — |